Early Detection Questionnaire
Diagnostic TestQuestionnaire for the Early Detection of Heart Failure
NCT Number: NCT07673562
The goal of this study is to assess the discriminatory power of a previously developed tool for detecting decompensated heart failure-which includes, in particular, clinical signs-in a population of patients hospitalized in cardiology units in Réunion. The main question it aims to answer is : Would a simple and rapid screening tool for decompensated heart failure help identify a high probability of this condition in a population hospitalized in a cardiology unit in Réunion? This study includes patients aged 55 and older, who reside in Réunion, who were admitted on an unscheduled basis to the cardiology department at the Réunion University Hospital or the Ouest Réunion Hospital, for any reason (whether as an inpatient or in the intensive care unit)
The study is conducted in two phases:
Phase 1: Development of the new e-DELPHI consensus-based screening tool Phase 2: Administration of the Déspist'IC-Run early detection tool for decompensated heart failure and performance of the gold standard cardiology examination (RIPH3)
Trial opening soon.
Get Notified55 year and older
All sexes
Observational
This is a preliminary, cross-sectional "diagnostic" ("screening") study (to assess validity relative to the gold standard test), conducted at two centers, evaluating a questionnaire that does not alter the patient's standard of care (prospective data collection).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients:
Exclusion criteria
Patients:
Questionnaire for the Early Detection of Heart Failure
Time frame: "From enrollment to the end of the study, at 6 month
The probability of having decompensated heart failure, as determined by a screening tool in the form of a questionnaire, will be calculated using the equation of a logistic regression model that explains the observed status (dependent variable) as determined by the gold standard test.
The gold standard test for establishing a definitive diagnosis of decompensated heart failure will combine three tests: a clinical examination by a cardiologist, a transthoracic Doppler echocardiogram (TTE), and an electrocardiogram.
Time frame: From enrolment to the end of the study, at 6 month
The detailed description of the tool's development phase is a task that complements statistical modeling (of the tool's development) and is purely epidemiological in nature.
Time frame: From enrollment to the end of the study at 6 months
The following characteristics are collected: age, sex, socioeconomic status, residential area (north, south, west, east); cardiovascular risk factors (hypertension, diabetes, dyslipidemia, known heart disease, history of myocardial infarction, end-stage renal disease requiring dialysis); lifestyle factors (Body Mass Index (kg/m²), physical activity > 30 min at least 3 times/week, current smoking, alcohol consumption > 3 drinks/day).
Time frame: From enrollment to the end of the study at 6 month
Socio-demographic data (age, sex, residential area) and clinical data (cardiovascular history) for the population with heart failure in Réunion, obtained from the SNDS, will be compared with those of the sample in this study
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de la Réunion
Other
Acronym: DEPIST'IC-RUN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07740044
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Taizhou, Jiangsu, China
View Trial DetailsNCT07737964
Cardiovascular Diseases, Heart Diseases
Amiens, France
View Trial DetailsNCT07731048
Cardiovascular Diseases, Heart Diseases
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT05996328
Cardiovascular Diseases, Heart Diseases
Ann Arbor, Michigan, United States
View Trial Details